stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
85.84
1.66
+1.97%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) EBITDA
Abivax SA Sponsored ADR's EBITDA for fiscal 2025 was −$277.2M, compared with −$186.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$338.0M. Over the past ten years it has ranged from −$277.2M (fiscal 2025) to −$23.3M (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 7 consecutive fiscal years. Abivax SA Sponsored ADR ranks 557th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$277.2M | — |
| FY2024 | −$186.0M | — |
| FY2023 | −$137.1M | — |
| FY2022 | −$67.8M | — |
| FY2021 | −$61.5M | — |
| FY2020 | −$45.1M | — |
| FY2019 | −$37.2M | — |
| FY2018 | −$23.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$97.4M | — |
| Mar 2026 | −$65.4M | — |
| Dec 2025 | −$81.3M | — |
| Sep 2025 | −$94.0M | — |
| 6 more quarters | Free account |
Against its own ten years
Low −$277.2M
High −$23.3M
Ten-year median
−$64.6M
Current reading's percentile
13
EBITDA against peers
| Company | EBITDA |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | $108.8M |
| AXSM Axsome Therapeutics, Inc. compare | −$139.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$186.2M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$204.6M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| ABVX Abivax SA Sponsored ADR | −$338.0M |
| PRAX Praxis Precision Medicines, Inc. compare | −$380.8M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item